SCHEMBL8345707

SCHEMBL8345707

Oc1cccc2ccc(-c3ncc[nH]3)nc12

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
METAP2 P50579 2/20 0.47
TSHR P16473 2/20 0.47
MMP2 P08253 1/20 0.47
CHRM1 P11229 1/20 0.47
COMT P21964 1/20 0.47
ADRA1A P35348 1/20 0.47
METAP1 P53582 1/20 0.47
HDAC8 Q9BY41 1/20 0.47
PLAU P00749 1/20 0.45
NCF1 P14598 1/20 0.45
ALOX12 P18054 4/20 0.44
ALDH1A1 P00352 3/20 0.44
CYP1A2 P05177 1/20 0.44
CYP3A4 P08684 1/20 0.44
CYP2C9 P11712 1/20 0.44
HPGD P15428 1/20 0.44
CYP2C19 P33261 1/20 0.44
HIF1A Q16665 1/20 0.44
HSD17B10 Q99714 1/20 0.44
KDM4E B2RXH2 4/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12075533 0.81 CCR1 (0.53) METAP2TSHRMMP2CHRM1COMT
SCHEMBL21767732 0.77 METAP2 (0.63) METAP2TSHRMMP2CHRM1COMT
SCHEMBL197279 0.75 NISCH (0.54) ADRA1AALDH1A1CYP1A2CYP3A4CYP2C9
SCHEMBL29579960 0.75 IDO1 (0.50) METAP2TSHRMMP2CHRM1COMT
SCHEMBL2651969 0.75 ALDH1A1 (0.59) TSHRALDH1A1CYP1A2CYP3A4CYP2C9
SCHEMBL19603066 0.74 METAP2 (0.59) METAP2TSHRMMP2CHRM1COMT
SCHEMBL17786644 0.73 LMNA (0.54) TSHRMMP2ALDH1A1CYP3A4HPGD
SCHEMBL27965643 0.73 RAB9A (0.65) METAP2TSHRMETAP1ALDH1A1CYP1A2
SCHEMBL14091615 0.73 PDE5A (0.58) METAP2TSHRMMP2CHRM1COMT
SCHEMBL6051223 0.72 KDM4E (0.57) METAP2TSHRMMP2CHRM1COMT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3440070-B1 MDR-REVERSING 8-HYDROXY-QUINOLINE DERIVATIVES MTA TERMESZETTUDOMANYI KUTATOKOEZPONT (HU) 2024-10-30 EP disclosed
US-11701374-B1 8-hydroxy quinoline derivatives for enhancing telomerase reverse transcriptase (TERT) expression SIERRA SCIENCES, INC. (US) 2023-07-18 US disclosed
US-10744127-B2 MDR-reversing 8-hydroxy-quinoline derivatives MAGYAR TUDOMÁNYOS AKADÉMIA TERMÉSZETTUDOMÁNYI KUTATÓKÖZPONT (HU) 2020-08-18 US disclosed
US-10744127-B2 MDR-reversing 8-hydroxy-quinoline derivatives MAGYAR TUDOMÁNYOS AKADÉMIA TERMÉSZETTUDOMÁNYI KUTATÓKÖZPONT (HU) 2020-08-18 US disclosed
US-20190151306-A1 MDR-REVERSING 8-HYDROXY-QUINOLINE DERIVATIVES MAGYAR TUDOMÁNYOS AKADÉMIA TERMÉSZETTUDOMÁNYI KUTATÓKÖZPONT (HU) 2019-05-23 US disclosed
US-20190151306-A1 MDR-REVERSING 8-HYDROXY-QUINOLINE DERIVATIVES MAGYAR TUDOMÁNYOS AKADÉMIA TERMÉSZETTUDOMÁNYI KUTATÓKÖZPONT (HU) 2019-05-23 US disclosed
WO-2017175018-A2 MDR-REVERSING 8-HYDROXY-QUINOLINE DERIVATIVES MAGYAR TUDOMÁNYOS AKADÉMIA TERMÉSZETTUDOMÁNYI KUTATÓKÖZPONT (HU) 2017-10-12 WO disclosed
US-9302993-B2 8-hydroxy quinoline derivatives PRANA BIOTECHNOLOGY LIMITED (AU) 2016-04-05 US disclosed
US-20150335635-A1 8-HYDROXY QUINOLINE DERIVATIVES PRANA BIOTECHNOLOGY LIMITED (AU) 2015-11-26 US disclosed
US-9169211-B2 8-hydroxy quinoline derivatives PRANA BIOTECHNOLOGY LIMITED (AU) 2015-10-27 US disclosed
US-20150094334-A1 8-HYDROXY QUINOLINE DERIVATIVES PRANA BIOTECHNOLOGY LIMITED (AU) 2015-04-02 US disclosed
US-8975278-B2 8-hydroxy quinoline derivatives PRANA BIOTECHNOLOGY LIMITED (AU) 2015-03-10 US disclosed
US-8975278-B2 8-hydroxy quinoline derivatives PRANA BIOTECHNOLOGY LIMITED (AU) 2015-03-10 US disclosed
US-20150025108-A1 8-HYDROXY QUINOLINE DERIVATIVES PRANA BIOTECHNOLOGY LIMITED (AU) 2015-01-22 US disclosed
US-7619091-B2 Treating nervous system disorders such as mild cognitive impairment, Alzheimer's disease or dementia associated with Down syndrome; e.g. use of 5,7-dichloro-8-hydroxy-2-(2-pyridyl)-quinoline (PBT 1052) PRANA BIOTECHNOLOGY LIMITED (AU) 2009-11-17 US disclosed
US-7619091-B2 Treating nervous system disorders such as mild cognitive impairment, Alzheimer's disease or dementia associated with Down syndrome; e.g. use of 5,7-dichloro-8-hydroxy-2-(2-pyridyl)-quinoline (PBT 1052) PRANA BIOTECHNOLOGY LIMITED (AU) 2009-11-17 US disclosed
US-20080161353-A1 8-Hydroxy quinoline derivatives PRANA BIOTECHNOLOGY LIMITED (AU) 2008-07-03 US disclosed
US-20080161353-A1 8-Hydroxy quinoline derivatives PRANA BIOTECHNOLOGY LIMITED (AU) 2008-07-03 US disclosed
WO-2004007461-A1 8-HYDROXY QUINOLINE DERIVATIVES PRANA BIOTECHNOLOGY LIMITED (AU) 2004-01-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190151306-A1 MDR-REVERSING 8-HYDROXY-QUINOLINE DERIVATIVES ABCC1, ABCB1, ABCC8 METAP2 3541/4885TSHR 4666/4885MMP2 2751/4885
US-20150335635-A1 8-HYDROXY QUINOLINE DERIVATIVES PARK7, COQ8A, NLN METAP2 1832/4885TSHR 3214/4885MMP2 1776/4885
US-20080161353-A1 8-Hydroxy quinoline derivatives PARK7, COQ8A, NLN METAP2 1832/4885TSHR 3214/4885MMP2 1776/4885
US-11701374-B1 8-hydroxy quinoline derivatives for enhancing telomerase reverse transcriptase (TERT) expression TERT, TERF2, RNGTT METAP2 1330/4885TSHR 2636/4885MMP2 761/4885
US-10744127-B2 MDR-reversing 8-hydroxy-quinoline derivatives ABCC1, ABCB1, ABCC8 METAP2 3541/4885TSHR 4666/4885MMP2 2751/4885
US-20150025108-A1 8-HYDROXY QUINOLINE DERIVATIVES PARK7, COQ8A, NLN METAP2 1832/4885TSHR 3214/4885MMP2 1776/4885
US-20150094334-A1 8-HYDROXY QUINOLINE DERIVATIVES PARK7, COQ8A, NLN METAP2 1832/4885TSHR 3214/4885MMP2 1776/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.